Indian Journal of Endocrinology and Metabolism

REVIEW ARTICLE
Year
: 2017  |  Volume : 21  |  Issue : 5  |  Page : 762--764

Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool


Sanjay Kalra1, AG Unnikrishnan2, Manash Baruah3, Pallavi Kawatra4, Jignesh Ved4 
1 Director, Bharti Hospital and BRIDE, Karnal, Haryana, India
2 Director, Chellaram Diabetes Institute, Pune, Maharashtra, India
3 Excel Center (Initiative of Excelcare Hospitals Pvt. Ltd.), Guwahati, Assam, India
4 Department of Medical Affairs, Boehringer Ingelheim, Mumbai, Maharashtra, India

Correspondence Address:
Sanjay Kalra
Bharti Hospital and BRIDE, Karnal - 132 001, Haryana
India

Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.


How to cite this article:
Kalra S, Unnikrishnan A G, Baruah M, Kawatra P, Ved J. Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool.Indian J Endocr Metab 2017;21:762-764


How to cite this URL:
Kalra S, Unnikrishnan A G, Baruah M, Kawatra P, Ved J. Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool. Indian J Endocr Metab [serial online] 2017 [cited 2021 Apr 11 ];21:762-764
Available from: https://www.ijem.in/article.asp?issn=2230-8210;year=2017;volume=21;issue=5;spage=762;epage=764;aulast=Kalra;type=0